Metraipolis › archive › dc_8dc8162d68db

Single-Institution Outcomes of Neoadjuvant Gemcitabine and Nab-Paclitaxel Combination in Borderline Resectable Pancreatic Adenocarcinoma: A Three-Year… — Europe PMC PMID:42291898

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42291898
DOI
10.7759/cureus.108823
License (as archived)
solo-consultazione
Archived
2026-11-02T07:35:06.594Z
SHA-256 of the archived text
0c274d75a023f531a987b2bf008b514bc197c50879f4587cf32b1525278caea5
Stable URL of this page
https://metraipolis.com/documento/dc_8dc8162d68db

How to cite

Single-Institution Outcomes of Neoadjuvant Gemcitabine and Nab-Paclitaxel Combination in Borderline Resectable Pancreatic Adenocarcinoma: A Three-Year… — Europe PMC PMID:42291898 — Europe PMC (en), https://europepmc.org/article/MED/42291898 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8dc8162d68db (Metraipolis archive dc_8dc8162d68db, sha256 0c274d75a023f531a987b2bf008b514bc197c50879f4587cf32b1525278caea5)
BibTeX
@misc{dc8dc8162d68db,
  title = {Single-Institution Outcomes of Neoadjuvant Gemcitabine and Nab-Paclitaxel Combination in Borderline Resectable Pancreatic Adenocarcinoma: A Three-Year… — Europe PMC PMID:42291898},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42291898},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8dc8162d68db; sha256 0c274d75a023f531a987b2bf008b514bc197c50879f4587cf32b1525278caea5},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42291898. Agents can read the archived copy with the MCP tool read_document.